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ABSTRACT Lipid rafts are specialized liquid-ordered (Lo) phases of the cell membrane that are enriched in sphingolipids and
cholesterol (Chl), and surrounded by a liquid-disordered (Ld) phase enriched in glycerophospholipids. Lipid rafts are involved in
the generation of pathological forms of proteins that are associated with neurodegenerative diseases. To investigate the effects
of lipid composition and phase on the generation of pathological forms of proteins, we constructed an Ld-gel phase-separated
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)/sphingomyelin (from bovine brain (BSM))-supported lipid bilayer
(SLB) and an Ld-Lo phase-separated POPC/BSM/Chl SLB. We used in situ time-lapse atomic force microscopy to study the inter-
actions between these SLBs and the prion peptide K106TNMKHMAGAAAAGAVVGGLG126 (PrP106–126) amide, numbered
according to the human prion-peptide sequence. Our results show that: 1), with the presence of BSM in the Ld phase, the
PrP106–126 amide induces fully penetrated porations in the Ld phase of POPC/BSM SLB and POPC/BSM/Chl SLB; 2), with
the presence of both BSM and Chl in the Ld phase, the PrP106–126 amide induces the disintegration of the Ld phase of
POPC/BSM/Chl SLB; and 3), with the presence of both BSM and Chl in the Lo phase, PrP106–126 amide induces membrane
thinning in the Lo phase of POPC/BSM/Chl SLB. These results provide comprehensive insight into the process by which the
PrP106–126 amide interacts with lipid membranes.INTRODUCTION
The ‘‘fluid mosaic model’’ for membrane structure was
described in 1972 (1). It promoted an enormous development
in the understanding of the structure and function of the cell
membrane. Twenty-five years later, ‘‘functional rafts’’ (also
named ‘‘lipid rafts’’) were proposed to exist as a specific
liquid-ordered (Lo) phase enriched in sphingolipids and
cholesterol (2). Since then, mounting scientific evidence
has confirmed the presence of ‘‘lipid rafts’’ (3–6). Lipid rafts
are clearly involved in the pathological processes of neuro-
degenerative diseases, including prion diseases (7–10) and
Alzheimer’s disease (10–12), but the specific pathological
roles of these lipid rafts remain unclear.
Prion diseases are characterized by an accumulation of the
abnormally misfolded, protease-resistant, b-sheet-rich path-
ological (scrapie) isoform (PrPSc) of the cellular prion
protein (PrPc) (13,14). Because full-length PrPSc is difficult
to isolate and characterize, investigators often use synthetic
K106TNMKHMAGAAAAGAVVGGLG126 (PrP106–126)
or an equivalent sequence as a substitute for PrPSc to study
the physicochemical and pathological properties of PrP
(15). Amino acids 106–126 are located in the unstructured
N-terminal region, adjacent to the well-ordered globular
domain of PrP. PrP106–126 appears to represent the neuro-
toxic core of PrP. The amphipathic primary structure of
PrP106–126 is characterized by two distinct regions: an
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0006-3495/09/06/4610/12 $2.00N-terminal hydrophilic region (K106TNMKHM112), and
a C-terminal hydrophobic region (A113GAAAAGAVVG
GLG126), providing favorable conditions for interacting
with cell membranes (16). Alternately, PrP106–126 has
many physiochemical qualities similar to those of PrP,
including partial protease resistance, high b-sheet content,
a propensity to form fibrils, and the ability to induce
nerve-cell degeneration in a number of different primary-
cell cultures (16–19). Reportedly, C-terminal amidation
could significantly reduce the neurotoxicity of PrP106–126
(20–22). Considering the poor temporal resolution (in
minutes) of atomic-force microscopy (AFM), the slow fibro-
genesis kinetics of PrP106–126 amide (the C-terminal
amidated form of PrP106–126) in physiological conditions
(22) make it an ideal model for studying its properties in lipid
membranes using in situ time-lapse AFM. Moreover,
comprehensive insights into the neurotoxicity of PrP106–
126 amide should arise.
Recent work indicated that PrP106–126 induces membrane
neurotoxicity by inducing the formation of ion-specific
permeable channels (23–25), membrane permeability, and
destabilization (26). We previously demonstrated that interac-
tions between PrP106–126 amide and a 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC) or POPC/cholesterol
(Chl) membrane involve semipenetrated poration (27). Little
attention has been paid to the effects of lipid rafts on peptide
behavior (23–27). Clearly, additional studies are needed to
understand the effects of changes in lipid structure and phase
on membrane pore formation (27).
In situ time-lapse AFM is a powerful tool for studying the
properties of membranes (28–33), the aggregation of
doi: 10.1016/j.bpj.2009.01.036
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membranes (36,37), and interactions between amyloid
peptides and membranes (27,38–41). In particular, AFM
can detect the phase separation of supported lipid bilayers
(SLBs) (42,43). Therefore, it offers an excellent method
for investigating lipid phases and biomolecular interactions
with SLBs at the molecular scale. Triton X-100 is one of
the most widely used nonionic detergents for purifying and
classifying lipid rafts (44). Triton X-100 extraction is useful
for differentiating phase separation in SLBs by AFM
(31,32,45,46). Under the same conditions, the Triton
X-100 resistances of specific phases are: Lo phase>gel
phase>liquid-disordered (Ld) phase (32).
Sphingomyelin (SM) is enriched in lipid rafts in the outer
leaflet of hippocampal neurons (47,48). Moreover, SM has
the same hydrophilic headgroup as POPC, but a dissimilar
hydrophobic backbone structure (49). Therefore, SM is
a good model lipid for neurodegenerative diseases, and is
also useful for investigating the hydrophobic backbone of
lipids. Cholesterol (Chl) is an important constituent of lipid
rafts, and plays an indispensable role in regulating the prop-
erties of eukaryotic cell membranes (3–5,10,50). Therefore,
SM and Chl are good model cell lipids when constructing
phase-separated SLBs. A phase diagram of the ternary
system of POPC/SM/Chl at room temperature was described
by De Almeida et al. (51) and Pokorny et al. (52).
We used brain sphingomyelin (BSM) and Chl to construct
a Ld gel phase-separated POPC/BSM SLB and a Ld-Lo
phase-separated POPC/BSM/Chl SLB. We used Triton
X-100 extraction to validate the presence of different phases
in SLBs. We confirmed previous results indicating that,
under the same conditions, Triton X-100 resistances are:
Lo phase>gel phase>Ld phase. Subsequently, we studied
the interactions of PrP106–126 amide with SLBs, using
in situ time-lapse AFM. We observed that, in contrast to
semipenetrated porations in POPC or POPC/Chl SLBs
(27), fully penetrated porations form in the Ld phase of
POPC/BSM SLB and POPC/BSM/Chl SLB because of the
presence of BSM. In addition, because of the presence of
both BSM and Chl, PrP106–126 amide induces Ld phase
membrane disintegration and Lo phase membrane thinning
in POPC/BSM/Chl SLB. These results provide comprehen-
sive insights into the process by which PrP106–126 interacts
with lipid membranes. The possible mechanisms underlying
interactions between PrP106–126 amide and POPC/BSM or
POPC/BSM/Chl lipid bilayers are discussed in light of our
results.
MATERIALS AND METHODS
Two different buffers were used for sample preparation and AFM imaging:
HEPES-buffered saline (HBS)-1 (50 mM HEPES, 100 mM NaCl, and 2 mM
CaCl2, pH 7.4) and HBS-2 (50 mM HEPES and 100 mM NaCl, pH 7.4). All
solutions were prepared with ultrapure water (18 MU $ cm1), and all solu-
tions were filtered through 0.2-mm filters before use. Synthetic POPC, BSM,
and Chl were purchased from Sigma-Aldrich (Saint Louis, MO). Wepurchased 1-aminonaphthalene-3,6,8-trisulfonic acid (ANTS) and N, N0-p-
xylylenebis (pyridinium) bromide (DPX) from Molecular Probes (Eugene,
OR). The PrP106–126 amide was synthesized manually by F-moc chem-
istry and purified by reversed-phase-high-performance liquid chromatog-
raphy, as described previously (27). The peptide was dissolved in water at
a concentration of 2 mM, and immediately frozen at 20C. The peptide
stock solution was thawed before use, and never frozen again. When the
stock solution was thawed and then dried on the freshly cleaved mica, no
aggregation was observed according to AFM in air (data not shown).
Preparation of SLBs in HBS-2
The SLBs in HBS-2 were prepared by the vesicle fusion method, as
described previously (27,53). Briefly, lipids were dissolved in chloroform/
methanol (2:1, v/v), dried in a rotary evaporator, and kept under high
vacuum overnight. The HBS-1 buffer at a volume of 400 mL was added
to the bottle to hydrate the lipid (1.0 mg/mL), and the solution was vortexed
vigorously until it became constantly milky. The solution was then extruded
through a 0.1-mm polycarbonate membrane (Avanti Polar Lipids, Alabaster,
AL) at 65C, to obtain large unilamellar vesicles (LUVs). Next, 80 mL of
LUV suspension were added to freshly cleaved mica (8 mm2) and incubated
at 70C for 2 h. Finally, the sample was slowly cooled and then carefully
rinsed with HBS-2 three times. The SLBs were maintained in an HBS-2
environment. According to our measurements, the SLBs were stable in
HBS-2 for several days at room temperature.
The packing density of the POPC-rich lipid domain was ~0.46 nm2 per
lipid molecule, and the packing density of the BSM-rich lipid domain was
~0.39 nm2 per lipid molecule (54). The amount of lipid on the mica surface
(8 mm2) was ~0.50 nmol. Because 10 random 10  10 mm-sized imaging
fields of each SLB showed no defects, we assumed that the prepared
SLBs had no defects. Because the total imaging volume of buffer was
100 mL, the lipid concentration on the mica surface was ~5.0 mM. Given
that cholesterol packs into the acyl chains of lipid bilayers as a molecular
spacer, the lipid concentration of POPC/BSM/Chl SLB on the mica surface
should be similar to that of POPC/BSM SLB.
In situ time-lapse AFM
In situ time-lapse AFM images were acquired in the solution-tapping mode
with a Nanoscope IV Multimode AFM (Veeco Instruments, Santa Barbara,
CA) with an EV-scanner at room temperature, as described previously (27).
We used sharpened OTR8 cantilevers (Veeco Instruments) with a nominal
spring constant of 0.15 N/m. The frequency of the cantilever oscillation
was tuned to 7–10 kHz, and the drive amplitude was adjusted to obtain
a root mean-square value between 1.0–2.0 V. The height images were re-
corded at a 512  512 pixel resolution, and the scan rate was 1.49 Hz. After
the addition of peptide (at a final concentration of 25 mM), the sample was
immediately scanned from top to bottom. All in situ time-lapse AFM exper-
iments were repeated three times on three independent bilayers. For every
independent bilayer, one representative area (10  10 mm) was used for
AFM experiments. All images were analyzed after treatment with ‘‘flatten’’
and ‘‘plane fit auto’’, using NanoscopeZ software (version 5.12r2, Veeco
Instruments). The height difference was measured using the ‘‘section’’ func-
tion, and the percentages of domain area and pores were analyzed using the
‘‘bearing’’ function in Nanoscope III software.
Detergent extraction
Triton X-100 stock solutions were prepared by dissolving Triton X-100
(16 mM) in water. These solutions were stored at room temperature. Deter-
gent-extraction experiments were performed with in situ time-lapse AFM.
Briefly, either POPC/BSM or POPC/BSM/Chl SLB was scanned and
imaged in liquid tapping mode. The tip was lifted, and Triton X-100 stock
solution was added, to a final concentration of 0.8 mM. The tip was engaged,
and the sample was immediately scanned from top to bottom.Biophysical Journal 96(11) 4610–4621
4612 Zhong et al.FIGURE 1 Construction and Triton X-100 extraction of SLBs. (a) In situ time-lapse AFM height images of Triton X-100 extraction of POPC/BSM
(1:1, mol/mol) SLB. (b) In situ time-lapse AFM height images of Triton X-100 extraction of POPC/BSM/Chl (45:45:10, mol/mol/mol) SLB. (c) AFM height
image of POPC/BSM/Chl (40:40:20, mol/mol/mol) SLB. Visual field is 10  10 mm. Height scale is 10 nm. Scan times before (0 min) and after injection of
Triton X-100 are given in each image. Black arrows in a and b indicate same position before and after injection of Triton X-100. Section Analysis (1): Gel
phases are ~0.8 nm higher than Ld phases along black line in image of 6 min in a. Section Analysis (2): gel phases are ~4.8 nm higher than the mica along the
black line in image of 6 min in a. Section Analysis (3): Lo phases are ~0.6 nm higher than Ld phases along black line in image of 0 min in b. Section Analysis (4):
Lo phases are ~5.4 nm higher than the mica along the black line in image of 6 min in b.Permeability assay of LUVs
The permeability of lipid vesicles was measured using the ANTS/DPX
assay, as described previously (27). Briefly, LUVs in a mixed solution
(12.5 mM ANTS, 45 mM DPX, 50 mM HEPES, and 20 mM NaCl,
pH 7.4) were prepared by extrusion through a 0.1-mm polycarbonate
membrane with an extruder (Avanti Polar Lipids) at 65C. Then the LUVs
were separated from the unencapsulated ANTS and DPX with a HiTrap
desalting column, using HBS-2 as elution buffer (Pharmacia Biotech AB,
Uppsala, Sweden). The collected LUVs were diluted to a concentration
below 100 mM. Fluorescence intensities were recorded with an F-4500 fluo-
rescence spectrometer (Hitachi, Tokyo, Japan) after 20 min of PrP106–126
amide treatment. The excitation wavelength was set at 355 nm, and the emis-
sion wavelength was 512 nm. Fluorescence intensities corresponding to 0%
and 100% leakage were determined before and after adding Triton X-100
(2.5%, v/v), respectively. All experiments were performed at 25C.
Circular dichroism spectra
Circular dichroism (CD) spectra were recorded on a spectropolarimeter
(model J-810, Jasco, Tokyo, Japan) at a peptide concentration of 50 mM
under a 0.02-cm path length. Three scans were accumulated and automati-
cally averaged in a wavelength range of 190–250 nm, with a 1-nm step reso-
lution. For CD spectra of peptide in a lipid environment, the peptide/lipidBiophysical Journal 96(11) 4610–4621molar ratio was 1:10. All CD spectra were measured at room temperature
(25C).
RESULTS AND DISCUSSION
Construction and Triton X-100 extraction
of phase-separated model systems
A typical AFM height image of the POPC/BSM (1:1, mol/mol)
SLB, whose composition is known via its phase diagram
to produce Ld-gel phase separation at room temperature
(51,52), is shown in Fig. 1 . Two coexisting phases are
evident: the brighter domains correspond to the BSM-
enriched gel phase, and the surrounding darker areas corre-
spond to the POPC-enriched Ld phase. The gel phase
comprised ~30.9%  6.8% of the bilayer (data were
analyzed from 20 different 10  10 mm imaging fields of
12 independent bilayers). These data demonstrate that
a proportion of BSM molecules was dispersed during the
Ld phase (54). The height difference between the two phases
was estimated at 0.8  0.1 nm (n ¼ 20; Fig. 1, Section
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this lipid system using liquid AFM (29,55).
Here, we chose Triton X-100 extraction as a tool for vali-
dating the structures and properties of model membranes. A
Triton X-100 solution was injected into the imaging solution,
and then the SLB was immediately scanned (with scan direc-
tion from top to bottom). About 3 min after injection, the gel
phase appeared to be considerably higher (Fig. 1 a, 6 min). It
then gradually solubilized and disappeared. After 12 min,
there were only a few spots (Fig. 1 a, lighter spots, 12 min),
demonstrating that the entire SLB was solubilized. The height
of the gel phase above the mica was measured at ~4.8 nm
(Fig. 1, Section Analysis (2)). Given that the height difference
between the two phases was estimated at 0.8  0.1 nm
(n¼ 20; Fig. 1, Section Analysis (1)), the measured height of
the Ld phase above the mica was found to be 4.0 nm, i.e., lower
than that of a pure POPC Ld phase (~5.0 nm; data not shown).
The POPC/BSM/Chl (45:45:10, mol/mol/mol) SLB
(Fig. 1 b, 0 min) was also observed to exist in two phases:
brighter domains correspond to the BSM/Chl-enriched Lo
phase, whereas the surrounding darker areas correspond to
the POPC-enriched Ld phase. The gel domains, which
should be present in the SLB according to the phase diagram
of the ternary system of POPC/BSM/Chl (51,52), might not
have been visible because their contribution was probably
too small (56). The sizes of Lo phases were found to be small
(several hundred nanometers in ‘‘diameter’’). These AFM
results are similar to those obtained for the POPC/BSM/
Chl (43:43:14, mol/mol/mol) SLB by Nicolini et al. (56).
The Lo phase comprised ~20.5%  4.4% of the bilayer
(data were analyzed from 20 different 10  10 mm imaging
fields of 12 independent bilayers). These data demonstrated
that a proportion of BSM molecules dispersed in the Ld
phase (54). The measured height difference between the
two phases was estimated at 0.6  0.1 nm (n ¼ 20; Fig. 1,
Section Analysis (3)), i.e., a little lower than that between
the gel and Ld phases in the POPC/BSM SLB. We also
attempted to increase the proportion of Chl, but found that
AFM could not detect the coexistence of two phases in
a POPC/BSM/Chl (40:40:20, mol/mol/mol) SLB (Fig. 1 c).
We thought it best to use a phase-separation SLB to inves-
tigate interactions between peptides and the lipid membrane.
Accordingly, we chose the POPC/BSM/Chl (45:45:10, mol/
mol/mol) SLB for our in situ time-lapse AFM experiments.
We also performed Triton X-100 extraction of the POPC/
BSM/Chl (45:45:10, mol/mol/mol) SLB. In Fig. 1 b,
(6 min), brighter domains (the Lo phase) appear to be consid-
erably higher after ~2 min. Then the Lo phase is gradually
solubilized and disappears (Fig. 1 b, 30 min and 54 min).
The measured height difference between the Lo phase and
the mica was 5.4  0.1 nm (n ¼ 20; see also Fig. 1 Section
Analysis (4)). Given that the measured height difference
between the two phases was estimated to be 0.6  0.1 nm
(n ¼ 20, see also Fig. 1, Section Analysis (3)), the measured
height of the Ld phase was ~4.8 nm.Morandat and El Kirat (31) demonstrated that the gel
phase of an L-a-dioleoylphosphatidylcholine (DOPC)/L-a-
dipalmitoylphosphatidylcholine (DPPC) SLB does not
completely disappear, even 70 min after adding 0.96 mM
Triton X-100. El Kirat and Morandat (32) demonstrated
that the gel phase of a DOPC/egg sphingomyelin (ESM)
SLB does not completely disappear, even 120 min after
the addition of Triton X-100, and the Lo phase of a DOPC/
ESM/Chl SLB does not disappear, even 120 min after the
addition of 0.96 mM Triton X-100. Here, however, the gel
phase of the POPC/BSM SLB and the Lo phase of the
POPC/BSM/Chl SLB disappeared a short time after adding
0.8 mM Triton X-100. This difference might be attributable
to the different lipid sources. In both our study and theirs, the
same Triton-100 resistances were observed, i.e., Lo pha-
se>gel phase>Ld phase. Triton X-100 resistance depends
on the stability of the lipid-lipid interaction relative to the
lipid-Triton X-100 interaction (57). The molecular packing
of BSM in the gel phase inhibits Triton X-100 insertion
and Triton X-100/lipid micelle formation (31). Two indepen-
dent factors concurrently inhibit the Triton X-100/lipid inter-
action in the Lo phase (58): 1), the molecular packing of
BSM and Chl in the Lo phase (59–61); and 2), the molecular
interactions between BSM and Chl, which are presumably
hydrogen bonds between the carbonyl group of BSM and
3b-OH of Chl (62,63). Thus, interactions between BSM and
Chl inhibit the insertion of Triton X-100 and the formation of
Triton X-100/lipid micelles (32). These interactions increase
the Triton X-100 resistance of the membrane. However,
molecular packing forces and molecular interactions do not
apply to POPC molecules in the Ld phase. Consequently,
the Lo phase has the strongest resistance to Triton X-100.
The gel phase is intermediate in resistance, and the Ld phase
is least able to resist Triton X-100 perturbation.
Our results also show that Chl increases the measured
height of membranes (Table 1). The measured height
(4.8 nm) of the Ld phase of the POPC/SM/Chl SLB was
found to be higher than that (4.0 nm) of the Ld phase of
the POPC/SM SLB. The measured height (5.4 nm) of the
Lo phase of the POPC/SM/Chl SLB was higher than that
(4.8 nm) of the gel phase of the POPC/SM SLB. Moreover,
the measured height difference (0.6 nm) between the
different phases of the POPC/SM/Chl SLB was lower than
that (0.8 nm) between the different phases of the POPC/
SM SLB. This result is consistent with previous work (64).
Cholesterol increases the length of POPC molecules by
orientating them in a more perpendicular fashion (28,65).
The BSM molecules cooperatively tilt in tandem during
the gel phase. In the Lo phase, however, Chl intercalates
between the chains of BSM, and thus reduces Chl’s ability
to tilt and thicken the BSM-enriched phases (65,66).
It is very important to be able to construct different lipid
phase systems when studying a protein’s interaction with
the membrane. We constructed four different supported lipid
bilayer model systems: POPC SLB and POPC/Chl SLB, asBiophysical Journal 96(11) 4610–4621
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SLB
Measured height
of Ld phase to mica (nm)
Measured height
of BSM-enriched (gel or Lo) phase
to mica (nm)
Height difference
between different phases (nm)
POPC/BSM (45:45, mol/mol) SLB 4.0 4.8 0.8
POPC/BSM/Chl (45:45:10, mol/mol/mol) SLB 4.8 5.4 0.6
BSM-enriched phase is gel phase in POPC/BSM (45:45, mol/mol) SLB, and Lo phase in POPC/BSM/Chl (45:45:10, mol/mol/mol) SLB.described previously (27), and POPC/BSM SLB and POPC/
BSM/Chl SLB, as described here. We believe it is useful
to investigate the effects that lipid composition and phase
exert on the interactions between proteins/peptides and
membranes. We can compare different phenomena in
the same phase of different model membrane systems, or
in different phases of the same model membrane system.
Here, we constructed a series of SLB model systems to
investigate interactions between proteins/peptides and
membranes.
Fully penetrated poration in the Ld phase
of a POPC/BSM SLB
To determine how BSM molecules affect interactions
between the membrane and the PrP106–126 amide at the
molecular level, we investigated interactions between
PrP106–126 amide and the POPC/BSM (1:1, mol/mol)
SLB with in situ time-lapse AFM (Fig. 2). After injecting
PrP106–126 amide, pores appeared in the Ld phase at
60 min (Fig. 2, b–d). These pores were not visible at earlier
times, even at 54 min (Fig. 2 a). Then, flat high-rise domains
(FHDs), which we determined previously to be peptide/lipid
phases induced by poration-medicated peptide diffusion in
the hydrophobic region of the membrane (27), formed and
diffused around the pores (Fig. 2, white arrows, 66 min).
Subsequently, FHDs expanded in size laterally, and gradu-
ally fused together over time (Fig. 2, 72, 78, 84, and
108 min). The FHDs comprised ~72.1%, and the gel phase
comprised ~18.9%, of the bilayer in the 108-min image.
The gel phase comprised ~26.9% of the bilayer in the
0-min image. Therefore, peptides can diffuse into the hydro-
phobic region of the gel phase and induce the formation and
expansion of FHDs. At 108 min, we added Triton X-100 to
the imaging solution, and immediately performed imaging.
As in the Ld phase, FHDs were easily solubilized by Triton
X-100 (Fig. 2, Triton X-100, 6 min), indicating that the inter-
actions between lipids and peptides were not sufficient to
resist Triton X-100 extraction. The measured height of the
gel phase from the mica was ~4.8 nm (Fig. 2, Section Anal-
ysis (2)), which is consistent with the measured height of the
gel phase obtained earlier (Fig. 1 a, Section Analysis (2)).
The measured height difference between the FHDs and the
Ld phase was ~2.2  0.1 nm (n ¼ 20). The greatest depth
of pores in the FHDs was ~5.6 nm (Fig. 2, Section Analysis
(1)). The depth of pores relative to the top surface of the Ld
phase was only 3.4  0.1 nm. Because the measured heightBiophysical Journal 96(11) 4610–4621of the Ld phase was ~4.0 nm (analyzed according to Fig. 1 a),
we assume that pores penetrated through the entire bilayer.
We also performed a leakage experiment with ANTS-
DPX to investigate the effects of PrP106–126 amide on
POPC/BSM membrane permeability (Fig. 3). Typically,
for POPC/BSM LUVs, we observed 64% leakage at a peptide
concentration of 50 mM, and 81% leakage at a peptide
concentration of 100 mM. The results of this membrane
permeability experiment are therefore consistent with the
AFM data. Nonetheless, the ANTS-DPX leakage experi-
ments and the in situ time-lapse AFM experiments showed
that PrP106–126 amide induces semipenetrated poration in
POPC or POPC/Chl SLBs (27). Consequently, BSM induces
the formation of fully penetrated poration, just as SM
increases the membrane permeability of melitin in the
ANTS-DPX leakage assay (67). These results show that
the poration mainly lies in the Ld phase, and rarely in the
gel phase, at the initial time (only a few pores formed in
the gel phase, e.g., the pore indicated by a black arrow in
Fig. 2, 78 min). Therefore, BSM in the Ld phase induces
the formation of fully penetrated poration. The lag time
(~60 min; Fig. 2) of poration in the POPC/SM SLB is longer
than that (~18 min) (27) of poration in the pure POPC SLB,
indicating that BSM increases the lag time of poration. In
short, BSM has two functions during the interaction between
PrP106–126 amide and POPC/SM SLB: 1), BSM induces
the formation of fully penetrated poration in the Ld phase;
and 2), BSM increases the lag time of poration.
To investigate the effect of lipids on the secondary struc-
tures of PrP106–126 amide, CD spectra were measured
(Fig. 4) with PrP106–126 amide incubated for 0 or 180 min
in three different environments: HBS-2, HBS-2-buffered
POPC LUV, and HBS-2-buffered POPC/BSM LUV. The
peptide/lipid molar ratio was 1:10. All spectra similarly pre-
sented a strong negative band at ~198 nm, i.e., a typical
random-coil conformation. The results with HBS-2 are
consistent with previous work (22). These results demon-
strated that POPC and BSM do not change the random-
coil conformation of PrP106–126 amide. The diffusions of
FHDs and pores in POPC/BSM SLB are summarized in
Fig. 5. The diffusion behavior resembles a part of a typical
S-shaped curve (Fig. 5 a). After an initial lag phase, the
average expansion rate of FHDs increases rapidly before
90 min (exponential growth phase), and decreases after
90 min (growth deceleration phase) (Fig. 5 b), in accordance
with typical S-shaped growth-curve behavior (68). During
the exponential growth phase, the percentage of pores
PrP106–126 Amide/Membrane Interaction 4615FIGURE 2 In situ time-lapse AFM images of PrP106–126 amide diffusion in POPC/BSM (1:1, mol/mol) SLB buffered by HBS-2. Visual field is 10 
10 mm. Height scale is 10 nm. (a–e) Zoomed-in images from regions, with corresponding letter labels. Circles indicate formed pores. White arrows indicate
FHDs. Black arrow indicates pore that occasionally forms during gel phase. Section Analysis (1): depth of deepest pore in FHDs is ~5.6 nm along black line in
image of 108 min. Triton X-100, 6 min: Triton X-100 extraction experiment after 108 min. Section Analysis (2): gel phases are ~4.8 nm higher than the mica
along the black line in image of Triton X-100 (6 min).increases with time prolonging (Fig. 5 c). In addition, the
average expansion rate of FHDs is proportionate to the
average percentage of pores (Fig. 5 d), reflecting that pores
sizes are more important in the diffusion of FHDs at lower
peptide densities in the hydrophobic core of lipid bilayers
(68). In the growth-deceleration phase, the slowing of the
expansion rate (Fig. 5, b and d) reflects an increasing envi-
ronmental (lipids and peptides) resistance that becomes
proportionately more important at higher peptide densitiesin the hydrophobic core of lipid bilayers (68). The diffusion
behavior of FHDs in POPC/BSM SLB is consistent with that
of FHDs in POPC or POPC/Chl SLB (27).
We proposed a peptide-induced poration model for POPC
and POPC/Chl membranes (27): the peptide binds to the
POPC membrane surface, leading to an increase of strain on
the membrane surface. Semipenetrated pores then form to
reduce this strain. The change from semipenetrated poration in
the POPC SLB to fully penetrated poration in the POPC/BSMBiophysical Journal 96(11) 4610–4621
4616 Zhong et al.SLB implies that fully penetrated poration undergoes two
semipenetrated porations: first, an upper leaflet-penetrated
poration, and then, lower leaflet-penetrated poration. Our
data regarding the POPC/BSM SLB show that porations
mainly lie in the Ld phase, and rarely in the gel phase.
Compared with a pure POPC SLB, a POPC/BSM SLB has
a portion of BSM molecules that are dispersed in the Ld phase.
In the Ld phase, BSM and POPC have the same membrane
surface-peptide binding ability because they have identical
hydrophilic heads. The binding of POPC to peptide easily
leads to a lateral expansion of the bilayer and a thinning of
the hydrophobic lipid core (69–71), which increases the
membrane strain. The sphingosine backbone of SM is more
rigid than the glycerol backbone of POPC, so the binding of
a peptide to an SM surface is less likely to increase membrane
strain. The presence of SM slows the formation of membrane
strain in the Ld phase. As a consequence, the lag time of pora-
tion (~60 min; Fig. 2) is longer than that in a pure POPC SLB
(~18 min) (27). When semipenetrated poration forms on the
upper leaflet of a POPC or POPC/Chl SLB, the peptide can
bind the exposed lipids on the lower leaflet to stabilize the
pores immediately, completing the formation of semipene-
trated poration (27). When upper leaflet-penetrated poration
forms in the Ld phase of a POPC/BSM SLB, however,
a peptide is less able to insert into the hydrophobic core
because of the rigidity of sphingosine. Therefore, the peptide
cannot bind the exposed backbones of BSM lipids on the
lower leaflet to stabilize the pores, and the exposed BSMs
and surrounding lipids are quickly released, causing a poration
on the lower leaflet of SLB. Therefore, fully penetrated
porations form during the Ld phase of a POPC/BSM SLB.
In the gel phase, because of the rigidity and tight packing
of sphingosine, BSM surface-peptide binding ability may be
FIGURE 3 Leakage of vesicle contents (ANTS/DPX) of a POPC/BSM
(1:1, mol:mol) LUV was induced by different concentrations of PrP106–
126 amide at 25C. Line on the graph is trendline of membrane leakage
versus peptide concentration.Biophysical Journal 96(11) 4610–4621lower than that of BSM in the Ld phase. Therefore, poration
does not occur efficiently in the gel phase. A small portion of
POPC molecules, however, do disperse in the gel phase (54).
Binding to peptide in the gel phase could induce membrane
strain. The formation of pores occurred occasionally in the
gel phase at initial time periods (Fig. 2, black arrow, 78 min).
These results indicate that the formation of pores in the gel
phase is less likely than in the Ld phase. After peptides
diffuse into the Ld phase through pores, however, they can
diffuse into the hydrophobic region of the gel phase and
induce the formation and expansion of FHDs.
To summarize, our results suggest that interactions
between PrP106–126 amide and a POPC/BSM SLB may
involve fully penetrated poration-mediated FHD diffusion,
which mainly occurs in the Ld phase because of the presence
of BSM (see Fig. 7 a). First, the peptide binds to the head-
group region of lipids in the Ld phase of the membrane. The
binding of peptide to the POPC surface increases membrane
FIGURE 4 The CD spectra of PrP106–126 amide incubated for 0 min or
180 min in three different environments (HBS-2, HBS-2-buffered POPC
LUV, and HBS-2-buffered POPC/SM LUV). All CD spectra present
negative adsorption at ~198 nm, a typical characteristic of random coils.
l: wavelength.
PrP106–126 Amide/Membrane Interaction 4617strain. The binding of peptide to the BSM surface does not,
however, increase membrane strain. Second, when a threshold
concentration of peptide on the surface of the Ld phase is
reached, the membrane releases vesicles containing the
FIGURE 5 Diffusions of FHDs and pores. (a) Area percentage (>) of
FHDs as a function of time. The line on the graph is a typical S-shaped
curve: y ¼ 100/[1 þ 10,112 * exp(0.096 * x)], where y is percentage of
FHD area at time x min. (b) Average expansion rate of FHDs during
AFM imaging interval (every 6 min). (c) Percentage (>) of pores as a func-
tion of time. (d) Average expansion rate of FHDs versus average percentage
of pores during AFM imaging interval (every 6 min). Data were fitted
by a linear equation (y ¼ a * x þ b). In the exponential growth phase,
y ¼ 2.84x  0.183, R2 ¼ 0.985; in the growth deceleration phase,
y ¼ 4.189x þ 5.939, R2 ¼ 0.644.peptide-upper leaflet lipid complex, causing upper leaflet-
penetrated poration and reducing the strain imposed on the
bilayer by the presence of the peptide chain. Third, near the
upper leaflet-penetrated pore, peptide binds to the exposed
POPC lipids, but not immediately to the exposed BSM lipid
hydrophobic core. Because the pores cannot be stabilized
in time, the lower leaflet continues to form lower leaflet-
penetrated pores. Therefore, fully penetrated pores form
during the Ld phase. At the same time, the peptide quickly
diffuses through the pores into the hydrophobic region of
the Ld phase of the lipid bilayer, and finally into the gel phase,
as indicated by the formation and expansion of FHDs.
Fully penetrated poration in POPC/BSM/Chl SLB
We also investigated the interaction between PrP106–126
amide and a POPC/BSM/Chl (45:45:10, mol/mol/mol)
SLB (Fig. 6). After the injection of PrP106–126 amide, the
Lo phase disappeared. Pores and FHDs appeared (Fig. 6,
18 min). Subsequently, the SLB was quickly ruined
(Fig. 6, 24 min and 30 min). In fact, we were unable to
engage the probe of AFM at the surface of the SLB until
~12 min, perhaps because of a block from the lipid-peptide
vesicles that were quickly released. The measured height
difference between FHDs and the top surface of the Ld phase
was 2.2  0.1 nm (n ¼ 20), which is similar to what was
observed in the POPC/BSM SLB-peptide interaction exper-
iments. The deepest pores on the FHDs were ~6.4 nm (Fig. 6,
Section Analysis (1)). Thus, the depth of pores from the top
surface of the Ld phase was 4.2 nm. Considering that the
measured height of the Ld phase of the POPC/BSM/Chl
SLB was 4.8 nm (analyzed according to Fig. 1 b), it appears
that pores penetrated the entire bilayer. This result is similar
to that observed for the POPC/BSM SLB. The BSM in the Ld
phase induced the formation of fully penetrated poration in
the Ld phase of POPC/BSM SLB. It is reasonable to specu-
late that the BSM in the Ld phase induced the formation of
fully penetrated poration in the Ld phase of the POPC/
BSM/Chl SLB via a similar mechanism. Firstly, the interac-
tion between peptide and POPC induces upper leaflet-pene-
trated porations. Then, BSM affects the interaction between
peptide and membrane, to form lower leaflet-penetrated po-
rations. In a POPC/BSM/Chl SLB, the pores are obviously
bigger (on a micrometer scale; Fig. 6, 18 min and 24 min)
than in a POPC/BSM SLB (Fig. 2). The sizes increase
with time until the whole SLB is nearly ruined (Fig. 6,
30 min). The POPC/Chl SLB-peptide interaction, which
we investigated previously (27), and the POPC/BSM SLB-
peptide interaction (Fig. 2), which we present here, do not
cause disintegration of the membrane. We conclude that
with the presence of both BSM and Chl, PrP106–126 amide
induces membrane disintegration. The interaction between
BSM and Chl, which are presumably hydrogen bonds
between the carbonyl group of BSM and 3b-OH of Chl
(62,63), might be the main cause of inducing membraneBiophysical Journal 96(11) 4610–4621
4618 Zhong et al.FIGURE 6 In situ time-lapse AFM height images of
PrP106–126 amide diffusion on a POPC/BSM/Chl
(45:45:10, mol/mol/mol) SLB buffered by HBS-2. Visual
field is 10  10 mm. Height scale is 10 nm. Scan times
before (0 min) and after the injection of peptide are given
in each image. To show complete height of a pore, the
height scale of Section Analysis (1) was adjusted to
13 nm. Section Analysis (1): FHDs are ~6.4 nm higher
than the mica along the black line in the image of 24 min.disintegration. When fully penetrated pores and FHDs form
in the Ld phase, the binding of peptide to BSM and Chl may
be not stable, and membrane disintegration occurs.
At 0 min, many Lo domains were dispersed in the Ld
phase. At 18 min, however, only pores, FHDs, and the
Ld phase were present. No Lo phases were dispersed in the
Ld phase, implying that the binding of peptide to the Lo
phase surface led to membrane thinning (36,69–71). The
height of the membrane-thinning domain is the same as the
height of the Ld phase. Three mechanisms were proposed
to explain peptide-induced membrane thinning (69): 1), the
formation of a lower leaflet/peptide complex reduces the
height of membrane-thinning domains to about half that of
the original membrane; 2), the formation of an asymmetric
lipid bilayer by lipid flip-flop reduces the height of
membrane-thinning domains to a height between that of
the Lo phase and of the Ld phase; and 3), an interdigitation
of bilayers occurs. We observed the same height between
the membrane-thinning domain and the Ld phase, ruling
out mechanisms 1 and 2. The only possible mechanism is
the interdigitation of bilayers, which induces the height of
membrane-thinning domains to be equal to that of the Ld
phase of the POPC/BSM/Chl SLB. The POPC/Chl SLB-
peptide interaction, as investigated previously (27), and the
POPC/BSM SLB-peptide interaction (Fig. 2), which we
present here, do not cause membrane thinning. We conclude,
therefore, that with the presence of both BSM and Chl in the
Lo phase, PrP106–126 amide induces membrane thinning.Biophysical Journal 96(11) 4610–4621Two reasons may be responsible for the membrane thinning:
1), PrP106–126 amide can induce membrane thinning during
the Lo phase; and 2), the interaction between BSM and Chl,
which are presumably hydrogen bonds between the carbonyl
group of BSM and 3b-OH of cholesterol (62,63), may induce
membrane thinning. When peptide interacts with BSM and
Chl in the Lo phase, it can insert into the hydrophobic core
of the Lo phase and induce membrane thinning.
In addition to the differences already noted between the
POPC/BSM/Chl SLB and POPC/BSM SLB, there are three
others: 1), the lag time of poration (<18 min) in the POPC/
BSM/Chl SLB was shorter than that (~60 min) in the POPC/
BSM SLB; 2), in midphase, more pores were formed in the
POPC/BSM/Chl SLB; and 3), the diffusion of FHDs in the
POPC/BSM/Chl SLB was faster than in the POPC/BSM
SLB. This comparison resembles that between the POPC/
Chl SLB and the POPC SLB (27). These differences
strengthen our previous hypothesis that Chl increases the
quantity of poration and decreases the rate of poration by
decreasing the threshold concentration of peptide for SLB
poration (27). This lowering of the threshold decreases the
lag time of poration in a Chl-containing SLB, compared
with a SLB without Chl.
We propose that the interaction between PrP106–126
amide and a POPC/BSM/Chl SLB involves membrane thin-
ning in the Lo phase, fully penetrated poration-mediated
FHD diffusion, and membrane disintegration in the Ld phase
(Fig. 7 b). First, the peptide binds to the lipid headgroups on
PrP106–126 Amide/Membrane Interaction 4619FIGURE 7 Schematics of possible
mechanisms by which PrP106–126
amide interacts with SLBs. (a) Interac-
tion between POPC/BSM SLB and
peptide. (b) Interaction between
POPC/BSM/Chl SLB and peptide. See
text for details.the membrane surface. Second, in the Lo phase, binding
quickly leads to membrane thinning; the height of the Lo
phase membrane-thinning domain equals that of the Ld
phase. To reduce the membrane strain induced by the peptide
binding to the membrane surface, the Ld phases release vesi-
cles of the peptide and upper-leaflet lipid. Third, because of
the presence of BSM, the vesicles of the peptide and lower-
leaflet lipid are released to cause fully penetrated poration. At
the same time, the peptide quickly diffuses into the lipid
bilayer through the pores, as indicated by the formation
and expansion of FHDs. Fourth, because of the presence
of BSM and Chl in the Ld phase, membrane disintegration
occurs. The membrane-thinning domains are also ruined.
This study relied only on AFM and membrane-perme-
ability experiments. Further work using fluorescence micros-
copy will be necessary to address the start position of
poration and peptide diffusion in the membrane. Additional
studies must address the destabilization of living cell
membranes by peptide binding, and would increase ourunderstanding of the membrane perturbation caused by
PrP106–126 amide. Differing from the semipenetrated pora-
tion observed in POPC and POPC/Chl SLBs, fully pene-
trated poration is induced by PrP106–126 amide in
a POPC/BSM SLB and a POPC/BSM/Chl SLB. Our studies
offer powerful support for the hypothesis that lipid structure
and membrane phases have enormous effects on the genera-
tion of pathological forms of proteins in neuronal diseases.
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